Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

6.8K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
6.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor microenvironment remodeling by STING agonism sensitizes endothelial cells to cytotoxic anti-PD-L1/L2 antibody.

Journal of experimental & clinical cancer research : CR·2026
Same author

IL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancer.

Scientific reports·2026
Same author

STING-induced blood-brain barrier opening combined with radiotherapy potentiates antitumor response in a high-grade glioma model.

The Journal of clinical investigation·2026
Same author

STING activation induces cytotoxic and immune responses in meningiomas via inflammatory cell death pathways.

Nature communications·2026
Same author

Voices: Future directions in targeting the tumor microenvironment.

Cell reports. Medicine·2025
Same author

NLRP3 Inflammasome Activation Expands the Immunosuppressive Myeloid Stroma and Antagonizes the Therapeutic Benefit of STING Activation in Glioblastoma.

Cancer research communications·2025

Related Experiment Video

Updated: Apr 19, 2026

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

15.7K

Immune checkpoint combinations from mouse to man.

Midan Ai1, Michael A Curran

  • 1Department of Immunology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit Number: 901, Houston, TX, 77030, USA.

Cancer Immunology, Immunotherapy : CII
|January 4, 2015
PubMed
Summary
This summary is machine-generated.

Antibody blockade of immune checkpoints like CTLA-4 and PD-1 shows promise in cancer immunotherapy. Combining these therapies may overcome tumor immune suppression and improve durable cures for more patients.

More Related Videos

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

4.2K
Production of Humanized Mouse via Thymic Renal Capsule Grafting, CD34+ Cells Injection, and Cytokine Delivery
05:15

Production of Humanized Mouse via Thymic Renal Capsule Grafting, CD34+ Cells Injection, and Cytokine Delivery

Published on: September 27, 2021

1.6K

Related Experiment Videos

Last Updated: Apr 19, 2026

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

15.7K
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

4.2K
Production of Humanized Mouse via Thymic Renal Capsule Grafting, CD34+ Cells Injection, and Cytokine Delivery
05:15

Production of Humanized Mouse via Thymic Renal Capsule Grafting, CD34+ Cells Injection, and Cytokine Delivery

Published on: September 27, 2021

1.6K

Area of Science:

  • Immunology
  • Oncology
  • Cancer Therapy

Background:

  • Antibody blockade of cytotoxic T lymphocyte-associated protein 4 (CTLA-4) revolutionized immunotherapy by restoring tumor immunity.
  • While effective, CTLA-4 blockade alone rarely cures cancer, necessitating exploration of other immune checkpoints.

Purpose of the Study:

  • To investigate the potential of combining immune checkpoint blockade therapies for enhanced cancer immunotherapy.
  • To identify optimal combination strategies for overcoming tumor immune suppression and minimizing toxicity.

Main Methods:

  • Review of preclinical studies and murine tumor models investigating T cell co-inhibitory and co-stimulatory receptors.
  • Analysis of existing data on CTLA-4 and programmed death 1 (PD-1) blockade monotherapies and their limitations.

Main Results:

  • Monotherapy with checkpoint inhibitors like CTLA-4 and PD-1 can lead to durable, immune-mediated cures in some metastatic cancers.
  • Tumors employ multiple redundant immune suppression mechanisms, limiting the efficacy of single-agent therapies.

Conclusions:

  • Combination immunotherapy targeting multiple immune checkpoints is crucial for extending curative potential to more patients.
  • Future research should focus on identifying synergistic combinations of co-inhibitory and co-stimulatory agents based on biological rationale and preclinical data.